intercostal muscles (101.1%, SEM 7.6) and sternomastoid muscles (58.0%, SEM 4.0). For western blots, 10-15 µg of protein was loaded and dystrophin (dys) was quantified relative to vinculin loading control. Samples from each tissue were run under the same experimental conditions and on the same SDS gel. For full SDS western gels see Supplementary Fig. 6.   Supplementary Fig. 4 . Immunohistochemical staining quantification in multiple skeletal tissues of exercised mdx mice following Pip6f-PMO treatment. Quantification of dystrophin protein in C57BL/10, mdx and Pip6f-PMO mdx mice for the diaphragm, tibialis anterior (TA), intercostal and sternomastoid muscles. Dystrophin expression is determined relative to laminin co-stain. Quantification is calculated using 120 regions of interest. This is calculated as the intensity value of dystrophin relative to the corresponding intensity value of laminin, normalised to C57BL/10 unexercised. The scatter plots show the normalised relative intensity values for each region of interest. Pip6f-PMO treatment resulted in widespread restoration of dystrophin expression in all tissues measured. Statistical significance was determined using ANOVA followed by Tukey post-hoc test (***=P <0.001, **= P <0.01*= P <0.05). Supplementary Fig. 5 . Full-length image of RT-PCR agarose gel showing Δ23 skipping in C57BL/10, mdx untreated and Pip6f-PMO treated mice following 12 week administration regimen. Heart, diaphragm, TA, intercostal muscles and sternomastoid muscles are shown. Supplementary Fig. 6 . Full-length images of western blots showing dystrophin protein expression and vinculin loading control in C57BL/10, mdx untreated and Pip6f-PMO treated mice following 12 week administration regimen. Heart, diaphragm, TA, intercostal muscles and sternomastoid muscles are shown. Supplementary Fig. 7 . Liver and kidney toxicity markers and biomarkers of muscle integrity in plasma samples of exercised mdx mice following Pip6f-PMO treatment. Graphs showing the measurement of plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, total bilirubin, urea, creatine kinase (CK) and lactate dehydrogenase (LDH) in C57BL/10 control mice compared to mdx untreated and treated mice. Statistical significance was determined using ANOVA followed by Tukey post-hoc test (***=P <0.001, **= P <0.01*= P <0.05). Note: ALT and AST-C57BL/10 cohorts significantly different to both mdx cohorts; P <0.0001.
Supplementary videos
Supplementary Video 1. Representative video illustrating running behaviour of mdx mice undergoing forced running on a treadmill. Mice were run on an Exer3/6 treadmill for 45 minute bouts. Mdx mice did not run consistently and required constant encouragement.
Supplementary Video 2.
Representative video illustrating running behaviour of C57BL/10 mice undergoing forced running on a treadmill. Mice were run on an Exer3/6 treadmill for 45 minute bouts. C57BL/10 mice ran well and consistently.
Supplementary Video 3.
Representative video illustrating running behaviour of Pip6f-PMO treated mice undergoing forced running on a treadmill. Mice were run on an Exer3/6 treadmill for 45 minute bouts. Treated mice ran well and consistently and did not require encouragement unlike the untreated mdx cohort.
